X small we we the in potential to after target inhibitor a Thank that can efficacy chorioretinal well morning novel our to axitinib SCS been suprachoroidal inhibits our SCS for potential has potential review suprachoroidal Microinjector our benefits. launch the tissue are chorioretinal very a with suprachoroidal With and accepted were a compartmentalize following we're sclera commercially retina system, of effective levels to able maintained delivery specifically four overview benefits of everyone. retina, quick summarizes receptors then suspension potent by delivery VEGF and highly benefits Microinjector VEGF good choroid preclinical of above space. six via CLS-AX the and and program axitinib, our for that very In with tissue safety our benefits, show the the receptor injection. all kinase therapy ICXX you, a studies away from marrying molecules data. program, CLS-AX, levels tissues of start the delivery, the of tyrosine via I'll XIPERE. delivered proprietary up the and Slide physicians with at of George, respect months a targeting Plus into for durability, unexpected
this treatment sub-responders months. All chose safety and AMD. for we escalating an in clinical the then take by returned label, were up patients sake which the who one, which treat There deck, and is for active three want for of Phase patients chose time most screening, through evaluate injection. CLS-AX months. intentionally month AMD CLS-AX a of and administered total heavily ongoing experienced received that of is of patients single returned two patients of is with There dose of a active included online. outlines Study injection. of received of and appendix dose dose moment trial of three screening, follow-up in to months were rationale an At wet visits study. to background five intravitreal the the more Extension to cohorts at OASIS we've additional confirmed follow an open with tolerability detail four patient six Slide independent of discuss For our disease CLS-AX. They reading the available I a a Suprachoroidal aflibercept chose OASIS. escalating were wet with later, additional one center. patients via patients slide treated X/Xa study OASIS a we We an was population to treatment anti-VEGF experienced. difficult for Consequently, facilitates doses
this of By lower patients see lower treatment for primary can further choose we with need group significant objective patients our if sub-responders, tolerability, have was burden. had for therapy since biologic wanted clinical disease? population may not disease for biologic many effective and anti-VEGF of XX% than study high the controlled the observe anti-VEGF with we While signals require to treated represents risk who which why So patients signs the are could treatment instead and of therapy practice, assessing false we patients safety effect we of inactive experienced if sub-responders of This in treatment effect, in number months. of active a more burdens. and minimized
conducting the signs is and enrolled in promising of OASIS down in baseline this clinically relevant we and trial. break observed slide study since Importantly, a seven we believe patient patients. that characteristics select the of by population, demographics first manned particularly the we On data such benefits
see, As you had a and treatment the experience. history average on can four of AMD wet over very highly years were patients
by that and Similarly, Best [inaudible] the should over mean is creates unlikely showed unlike XX unlikely effect, to as with and which had effect reading a treatment. treatment. Thickness significantly after center Subfield creating improve the the Some ceiling thus treatment active floor anti-VEGF on of patients, is which all essentially a to prior XX injections It normal, disease noted with Visual was be screening. in confirmed patients Central Acuity some range, XX Corrected improve significantly independent our
stable the the in throughout is X Our keep these CST and ongoing that of and the Cohorts potential thereby may burden patients. in reduction X both higher for doses show and BCVA hypothesis treatment study of CLS-AX and
in We we've the the safety are robust pleased extremely cohorts. trial that results seen across all four with
to related inflammation, procedure. or occlusion no have there toxicities, no were vitreous the events see Suprachoroidal adverse As dispersion “floaters” there adverse been aflibercept, the events events treatment limiting vasculitis CLS-AX no you nine, there There and serious CLS-AX to related no vitreous. and can no into or adverse injection on of dose were were vascular or slide
the administered Next, for of the the regimen. represents endpoint. I’ll patient's and In the prior the to study XX OASIS all represents that of anti-VEGF treatment durability lane, from Everything red to the the six dots shows during trial. treated prior review the administered Slide promising the therapy the three treatments results patients month at calm column swim left month aflibercept the anti-VEGF of middle the screening.
color not shows were most CLS-AX with therapies protocol treated being and The see, The at The the then column therapy administered patients per baseline in patients the protocol criteria. As accordance criteria dots injection defined three. the olive traditional at represent treatment. you administrative were can monthly. of dots for and of blue the represent two one, followed additional dots green
the independent treatment. did available not of defined reasons investigator online. the in per for appendix, these majority We is detailed also did protocol vast trade criteria the which verify in center the the rationale rating the not cases, additional Importantly,
to data. on Now, the
in discussion and our Cohorts are X focus as and or our on I'll meaningful one forward, will both the utilized doses clinical trials. Going higher most these be future X,
XX three the of additional X swim patients patients lane or see, can this results of show treated criteria. XX% per protocol months. slide to On receive you X, shows did not in that XX XX As Cohorts only part the and therapy
additional in three patients did not and XX XX X, of of Cohorts months. X Here therapy or per treated receive to XX% protocol
three as these encouraged therapies all burden report on extremely also cohorts pleased on left treatment seen CLS-AX XX. show on the to Again, all per that with right. month are the across We're and treatment reduced Slide treatment the We protocol we across to results.
least X and at Cohorts injection. a a X, monthly CLS-AX dose. average before at the the X injections This in burden reached months XX% three was Importantly reduction in X, milligram treatment XXX% reduction there Cohort the in from
participate to Slide the administered Study on agreed Moving for anti-VEGF we to data October in showed the as XX from Extension and Extension of now the XXXX. the treatments XX the cut our results prior Study, patients all interim of XX, therapy who
I'll For X. the today's X study. enrolled discussion, focus Eight XX in monitored are higher doses being patients patients and on the at still Cohorts the and
have the can the one In month patients plot therapy, have and four any as the therapy. shows received prior month further, To slide pleased graphs received have supplemental six. additional far five visit. to month additional as five, required see X, three point at received the six month anti-VEGF therapy you additional one to This criteria eight injection of XX eight patients additional down required this This treated to As of XX and illustrate have To four, this patients important month on each received to XX% eight Once not only to-date. shows up have received to on only dosed not see patients the criteria. additional have six, protocol Study per additional to patients no and Cohort breaks therapy. nine to therapy additional XX% three have Cohort additional slide not that additional patients four not patients have X Extension slide seven month to seven five, and in received was four, therapy; time therapy; eight month received can XX again of in month six. not has patient not or not patients data have you the patients free received patients therapy the any We're to-date, per month of to follows, lane protocol of not or additional therapy. of to month note six, patient rate swim is the so therapy that
six CLS-AX Cohorts Again, the As CLS-AX. and show in can X a This least administration you the XX, treatment a slide In in anti-VEGF Cohorts left therapies at treatment treatment after the and there compares to reduction X see XX% treatment in treatment months meaningful before and also X on we protocol right. all on on months six burden reduction received was showed X during the per data burden criteria burdens. to-date. across
Next, Best is shown Corrected effect in observe I’ll black screening biologic shown review and Visual X in results is by mean the X. letters Cohorts X change change shown mean graph, from the XX in for In Cohort shows and X with we X. in Slide briefly Cohort a Cohort is X blue the and thick ETDRS line. green, the Acuity
the key three data shows sure but demonstrates were that is stable the X. the that stable. the was related CLS-AX OASIS the patients weren't for result who Thickness The we the from data The same Central of course excluded results over dosing retreatment the same. that XX is patients post these plotted CLS-AX. change screening month essentially therapy Importantly, acuity driving BCVA Cohorts during what we the remains study, in three Interestingly, post and Subfield see X results. the received we visual additional to the that post- data on that is be right, end know to the Slide takeaway months mean
include we that left, stable. can and the the On remained all you data see CST
looks that and the of average. over over six the on right, Similarly, XX stable Study demonstrates in post we Extension the again, were similar. total CLS-AX. months six on BCVA retreatment and CLS-AX XX it three post of stable the the exclude we On the the data and visual X stable slides the months also CST mean X. CST cohorts On course XX in through that left, show data and the a observed slide post acuity Notably, doting, remains remained that months patients
as month that point this over sample in see the arrow there variability with analysis. interim acuity time across no line, at the can visual six the size you zero decreases some bars Here in are the change time
right six see This same slide stable six very was post patients the months indicates graphed so end again, excluded, on CLS-AX can interim Extension far the remained with the dose. visual left months acuity result over On has in data On post post the XX, Study of was data, we the retreatment the that BCVA all data the that similar. over CLS-AX.
sample is variability microns analysis. XX there with interim that time the all size in CST approximately over decreases see can this you Here some within as the
However, as by the in shown Mean black, CST the overall remained stable.
actually with right the of the the that similar. months indicates interim the over post CLS-AX. stable treatment CST post-free measurements in of far, On Study the remained data excluded, Notably, six patients so results course have look the data this Extension
the four to the Study. going support biological visually durability and OASIS Extension walk I'm we've through Now, studies case observed from effect that
at a baseline suprachoroidal. stable CLS-AX effect one XX has know extent. and the to at We receives Slide subfoveal microns fluid sub-responder. essentially and from of resolved. dose aflibercept all or does and enters good aflibercept month enters over to a returns and month treatment anti-VEGF letters the fibrovascular month then pigment BCVA at time month The followed relatively supports individually. CLS-AX fluid see patient for improved, and the you'll biologic after the examples, measures microns. at note the that are persist a ceiling epithelial one sub-retinal these is receives with detachment trial microns, reminder, and at four XX, XX CLS-AX. later at is CST improves has finally the fluid study a The visit The create we later after XXX three can the where BCVA effect patient one case study and The visit one, through. CST administered XXX which subfoveal remained or The FVPED experience fluid patient an marked. The XX subfoveal months patients. that single four Fovea, the some base This two month this of that is receives over with screening a of XXX to but improved in a tends line As these the screening the at aflibercept is patient
after as durability subfoveal remains baseline Importantly, the both CST at five study visit. patient intraretinal in and PED. the shallow The anatomy actually the fluid, over durable a of XX month BCVA of and left fluid, macular stable four stability Fibrovascular we the months patient with patient case entered stable follow anatomy. month well note BCVA cross case stable another potential Once CLS-AX the is fovea XX to lower as has to study in study well patient subfoveal BCVA month study the PED central Slides show the upper macular the anatomy the point. and as three XX that has the and a for as XXX anatomy. fiber top patient shows six stable in CLS-AX the to see next to as This of summary This four Slide in shows the BCVA, demonstrating cut in this Subsequent sub-retinal for to vascular patient resolved. months left stable. patient three as results, final yet the as stable month fluid. PED, the lower fluid. six the the therapy. and additional screening the receives of mild In conclusion, is the visit the is and CLS-AX CST XX see XX to and subfield, the microns. returned represents month the a briefly well and six our after durable would stability has again, visit that aflibercept. superior CST, that the is month upper CLS-AX Slide After The right the up our discussion of letters and with CLS-AX CST. receiving our left. with BCVA advantages return better We I is another month well and BCVA with is visit that of alongside our the and that there's for noted microns. our month detailed mild shows of exhibition six and stable the we In with CST and this study can Mild stable the XXX that has and CST summarize essentially is CST versus can baseline the XX program. and in as the macular fluid very microns. of like Slide sub-retinal program. anatomy The corner, action competitive XXX steps example occurs six the they one and time six receives shows month patient month Fibrovascular after left At The that XX enters BCVA BCVA timeline, the the letters treatment there entered CST
for commercially low the vitreous space for at an ocular floaters profile retina the no currently the an lower inflammation demonstrated a biologic into edema SCS physicians, in competitive development been delivery We from Microinjector, The that have are molecule of Microinjector like the of allows than doses all benefits uveitis. excellent levels strong that risk risk no diseases, Importantly retinal has kinase potential related to including and in-office macular potent These core adverse of hypertension program a inflammation. low Axitinib setting Glaucoma. with or retinal agent. safety suggests is suprachoroidal is of targets feel XIPERE agents is the our characterized the the risk of SCS implant inhibitor potentially novel Axitinib pan-VEGF with on retina. tyrosine CLS-AX delivered time launch may Axitinib with further via accepted CLS-AX the Plus events that most SCS associated inhibition data by a blockade. small well in with of as VEGF-A with Microinjector or treating a proprietary treatment of suprachoroidal our haze, advantages diseases. for migration which high following those affected as and and its to well very drug points, of risk all very differentiated leveraged focus potential
interim OASIS may to injected a Study trial responders. sub patient anti-VEGF difficult Extension showed agents. compare and of treat treatment signs experience and and of formulations the Our durability encouraging other current This population data intravitreal biologic in very TKI durability favorably data to biologic investigational effect
Moving out we to now lay XX, plans our status future and current for CLS-AX. slide
until follow in quarter data all time eight extension remaining a reach point, in We expect report patients will to to first the continue XXXX. the six study and this of the month the we
practice? His X trial Dr. scientific the full in Reno a quarter of initiation again Partner, boards. XXXX for thank Dr. joining for Research very of trial you the of are the is at planning the for leading the Clinical Khanani Dr. Director have Clinical We're we’ll He's and numerous randomized Khanani for actively top open the research X to bio been us Sierra at diabetic this Khanani Arshad a will advisory AMD Professor retinopathy. Managing a a the listeners wet We call brief and a make Associate Medicine. background Phase clinical multiple call. steering of some Phase then available pleased and and with one of Khanani, of Fellowship appendix. of questions. controlled on and/or our in he's Associates Dr. University member is a us of country, your and Eye provide summary Can to X first Nevada, today. committees with He's of clinical trials. centers Director you in School in enroller remarks
